Novo Holdings A/S 3
3 · Avalyn Pharma Inc. · Filed Apr 29, 2026
Insider Transaction Report
Form 3
Novo Holdings A/S
10% Owner
Holdings
Series A Preferred Stock
[F1]→ Voting Common Stock (935,466 underlying)Series B Preferred Stock
[F1]→ Voting Common Stock (103,232 underlying)Series C-1 Preferred Stock
[F1]→ Voting Common Stock (1,345,997 underlying)Series C-2 Preferred Stock
[F1]→ Voting Common Stock (290,390 underlying)Series D Preferred Stock
[F1]→ Voting Common Stock (652,649 underlying)
Footnotes (1)
- [F1]The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock is convertible on a 1-for-19.2417 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.
Signature
/s/ Barbara Fiorini, General Counsel, Finance & Operations of Novo Holdings A/S|2026-04-29